|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
2
|
Siegel R, DeSantis C, Virgo K, et al:
Cancer treatment and survivorship statistics, 2012. CA Cancer J
Clin. 62:220–241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Weinstein IB: Cancer. Addiction to
oncogenes - the Achilles heal of cancer. Science. 297:63–64. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Paez JG, Janne PA, Lee JC, et al: EGFR
mutations in lung cancer: correlation with clinical response to
gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pao W, Miller V, Zakowski M, et al: EGF
receptor gene mutations are common in lung cancers from ‘never
smokers’ and are associated with sensitivity of tumors to gefitinib
and erlotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004.
|
|
7
|
Mok TS, Wu YL, Thongprasert S, et al:
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N
Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Soda M, Choi YL, Enomoto M, et al:
Identification of the transforming EML4-ALK fusion gene in
non-small-cell lung cancer. Nature. 448:561–566. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kwak EL, Bang YJ, Camidge DR, et al:
Anaplastic lymphoma kinase inhibition in non-small-cell lung
cancer. N Engl J Med. 363:1693–170. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shaw AT, Kim DW, Nakagawa K, et al:
Crizotinib versus chemotherapy in advanced ALK-positive lung
cancer. N Engl J Med. 368:2385–2394. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Seto T, Kiura K, Nishio M, et al:
CH5424802 (RO5424802) for patients with ALK-rearranged advanced
non-small-cell lung cancer (AF-001JP study): a single-arm,
open-label, phase 1–2 study. Lancet Oncol. 14:590–598.
2013.PubMed/NCBI
|
|
12
|
Brown JM and Wilson WR: Exploiting tumour
hypoxia in cancer treatment. Nat Rev Cancer. 4:437–447. 2004.
View Article : Google Scholar
|
|
13
|
Minakata K, Takahashi F, Nara T, et al:
Hypoxia induces gefitinib resistance in non-small-cell lung cancer
with both mutant and wild-type epidermal growth factor receptors.
Cancer Sci. 103:1946–1954. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Murakami A, Takahashi F, Nurwidya F, et
al: Hypoxia increases gefitinib-resistant lung cancer stem cells
through the activation of insulin-like growth factor 1 receptor.
PLoS One. 9:e864592014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Arao T, Fukumoto H, Takeda M, Tamura T,
Saijo N and Nishio K: Small in-frame deletion in the epidermal
growth factor receptor as a target for ZD 6474. Cancer Res.
64:9101–9104. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tanaka K, Arao T, Maegawa M, et al: SRPX2
is overexpressed in gastric cancer and promotes cellular migration
and adhesion. Int J Cancer. 124:1072–1080. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kaneda H, Arao T, Tanaka K, et al: FOXQ1
is overexpressed in colorectal cancer and enhances tumorigenicity
and tumor growth. Cancer Res. 70:2053–2063. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee JM, Dedhar S, Kalluri R and Thompson
EW: The epithelial-mesenchymal transition: new insights in
signaling, development, and disease. J Cell Biol. 172:973–981.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013.PubMed/NCBI
|
|
20
|
Wheelock MJ, Shintani Y, Maeda M, Fukumoto
Y and Johnson KR: Cadherin switching. J Cell Sci. 121:727–735.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Harris AL: Hypoxia - a key regulatory
factor in tumour growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jiang J, Tang YL and Liang XH: EMT: a new
vision of hypoxia promoting cancer progression. Cancer Biol Ther.
11:714–723. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Choi YL, Soda M, Yamashita Y, et al:
EML4-ALK mutations in lung cancer that confer resistance to ALK
inhibitors. N Engl J Med. 363:1734–1739. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Katayama R, Shaw AT, Khan TM, et al:
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung
cancers. Sci Transl Med. 4:120ra172012.PubMed/NCBI
|
|
25
|
Katayama R, Khan TM, Benes C, et al:
Therapeutic strategies to overcome crizotinib resistance in
non-small cell lung cancers harboring the fusion oncogene EML4-ALK.
Proc Natl Acad Sci USA. 108:7535–7540. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tanizaki J, Okamoto I, Okabe T, et al:
Activation of HER family signaling as a mechanism of acquired
resistance to ALK inhibitors in EML4-ALK-positive non-small cell
lung cancer. Clin Cancer Res. 18:6219–6226. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim HR, Kim WS, Choi YJ, Choi CM, Rho JK
and Lee JC: Epithelial-mesenchymal transition leads to crizotinib
resistance in H2228 lung cancer cells with EML4-ALK translocation.
Mol Oncol. 7:1093–1102. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sakamoto H, Tsukaguchi T, Hiroshima S, et
al: CH5424802, a selective ALK inhibitor capable of blocking the
resistant gatekeeper mutant. Cancer Cell. 19:679–690. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Friboulet L, Li N, Katayama R, et al: The
ALK inhibitor ceritinib overcomes crizotinib resistance in
non-small cell lung cancer. Cancer Discov. 4:662–673. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chiou SH, Wang ML, Chou YT, et al:
Coexpression of Oct4 and Nanog enhances malignancy in lung
adenocarcinoma by inducing cancer stem cell-like properties and
epithelial-mesenchymal transdifferentiation. Cancer Res.
70:10433–10444. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Scheel C and Weinberg RA: Cancer stem
cells and epithelial-mesenchymal transition: concepts and molecular
links. Semin Cancer Biol. 22:396–403. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rho JK, Choi YJ, Lee JK, et al: Epithelial
to mesenchymal transition derived from repeated exposure to
gefitinib determines the sensitivity to EGFR inhibitors in A549, a
non-small cell lung cancer cell line. Lung Cancer. 63:219–226.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Suda K, Tomizawa K, Fujii M, et al:
Epithelial to mesenchymal transition in an epidermal growth factor
receptor-mutant lung cancer cell line with acquired resistance to
erlotinib. J Thorac Oncol. 6:1152–1161. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sequist LV, Waltman BA, Dias-Santagata D,
et al: Genotypic and histological evolution of lung cancers
acquiring resistance to EGFR inhibitors. Sci Transl Med.
3:75ra262011.PubMed/NCBI
|
|
35
|
Kobayashi Y, Sakao Y, Ito S, et al:
Transformation to sarcomatoid carcinoma in ALK-rearranged
adenocarcinoma, which developed acquired resistance to crizotinib
and received subsequent chemotherapies. J Thorac Oncol. 8:e75–e78.
2013. View Article : Google Scholar
|
